Essentials: Compulsive Behaviors & Deep Brain Stimulation | Dr. Casey Halpern
Dr. Casey Halpern, chief of stereotactic functional neurosurgery at Penn Medicine, discusses deep brain stimulation (DBS) as a treatment for OCD, binge eating disorder, and other compulsive behaviors. He explains the neuroscience behind the nucleus accumbens and reward circuits, and explores both invasive and non-invasive brain intervention approaches. He also discusses the future role of machine learning and wearable technology in detecting and preventing compulsive episodes.
Summary
Dr. Casey Halpern, a neurosurgeon specializing in deep brain stimulation (DBS) at Penn Medicine, provides a detailed overview of his work treating severe psychiatric and neurological conditions through surgical brain intervention. He begins by distinguishing neurosurgery from other brain-focused specialties, noting that his subspecialty focuses entirely on DBS and focused ultrasound — procedures that deliver precisely targeted electrical stimulation or thermal ablation to small brain regions.
Dr. Halpern describes OCD as a spectrum disorder involving hyperactive prefrontal and orbitofrontal cortex activity, along with dysregulation in subcortical structures like the basal ganglia and nucleus accumbens. He explains that first-line treatments include SSRIs, tricyclics, and exposure-response prevention therapy (a form of CBT), but approximately 30% of patients remain treatment-resistant. For these severe cases, DBS or capsulotomy (ablative lesioning) are considered, though current responder rates are only around 50% and even responders still exhibit symptomatic OCD.
A central theme of the discussion is the nucleus accumbens and its role in reward-seeking and compulsive behavior. Dr. Halpern explains that this structure, when dysregulated, drives compulsive pursuit of rewards despite negative consequences — a pattern common across OCD, addiction, binge eating disorder, and bulimia. He describes efforts to identify 'craving cells' in the nucleus accumbens of patients with binge eating disorder, analogous to tremor cells identified in Parkinson's patients, with the goal of developing closed-loop DBS systems that stimulate the brain only when craving signals are detected.
Dr. Halpern discusses the use of stereoencephalography (SEEG) — a technique borrowed from epilepsy surgery — to place multiple thin invasive electrodes throughout the brain to map neural activity associated with psychiatric symptoms. He highlights collaborative work at Baylor and UCSF using this approach to study depression circuits, with the long-term goal of identifying consistent targets that could eventually be treated non-invasively via focused ultrasound or TMS.
On non-invasive approaches, Dr. Halpern acknowledges that TMS is FDA-approved for depression, OCD, and nicotine addiction, and that focused ultrasound is FDA-approved for tremor. He expresses optimism about expanding these methods to psychiatric and metabolic disorders but emphasizes that better target identification — ideally through invasive human studies — is needed before non-invasive treatments can be made precise and reliable.
The conversation also touches on the role of machine learning and AI in predicting compulsive or suicidal episodes before they occur, referencing research at the University of Washington using voice patterns and physiological signals. Dr. Halpern acknowledges that while surgery can only reach the most severe patients, insights from invasive brain research could help scale solutions for widespread public health crises including obesity, opioid addiction, depression, and suicidality.
Key Insights
- Dr. Halpern argues that OCD exists on a spectrum and that subclinical obsessive-compulsive traits can be functional assets — such as in surgeons or CEOs — but become pathological when they are uncontrollable and disruptive to daily life.
- Dr. Halpern claims that a common neurological denominator across OCD, addiction, eating disorders, and suicidality is the nucleus accumbens-driven 'urge despite the risk' — the compulsive pursuit of reward or relief even when harmful consequences are known.
- Dr. Halpern describes a novel intraoperative approach where patients with binge eating disorder are kept awake during DBS electrode placement so that 'craving cells' in the nucleus accumbens can be identified by their electrical signatures, analogous to tremor cell identification in Parkinson's surgery.
- Dr. Halpern argues that current DBS outcomes for OCD are suboptimal, with roughly a 50% responder rate, and that even responders still have symptomatic OCD, underscoring the need for more targeted, symptom-specific stimulation strategies.
- Dr. Halpern contends that for the most severe patients with binge eating disorder, awareness of their behavior is not the limiting factor — even under laboratory surveillance with full awareness, patients still binge because they genuinely cannot control the behavior.
- Dr. Halpern argues that non-invasive brain stimulation methods like TMS and focused ultrasound lack sufficient precision because the field does not yet know the optimal targets, and that invasive human brain recordings are essential to defining those targets before non-invasive therapies can be effective.
- Dr. Halpern describes a closed-loop DBS paradigm being developed for binge eating disorder in which the implanted device detects a neural craving signal and automatically delivers stimulation to interrupt the craving before a binge occurs, rather than delivering continuous stimulation.
- Dr. Halpern asserts that machine learning and physiological monitoring (e.g., voice patterns, sleep data) could potentially anticipate impulsive or compulsive episodes before they reach conscious awareness, pointing to University of Washington research on predicting suicidal depressive episodes as a proof-of-concept.
Topics
Full transcript available for MurmurCast members
Sign Up to Access